Protalix publishes corporate presentation highlighting Elfabrio commercialization and PRX-115 Phase 2 gout study
Reuters2026/08/12 11:28- Protalix highlighted profitability with net income of $22.1 million for the first half of 2026.
- Cash and cash equivalents of $40.7 million as of June 30, 2026; no debt; no warrants.
- Total revenues of $53.6 million year to date; included a $25 million Chiesi milestone in Q1 2026.
- Second-quarter revenue from selling goods rose to $19.8 million, driven by Elfabrio sales.
- PRX-115 Phase 2 trial in uncontrolled gout is enrolling; topline data targeted for 2H 2027.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Why hasn’t the rise in US Treasury yields boosted the US dollar exchange rate?
Gurman predicts iPhone Duo: The first foldable may set industry standards, Apple (AAPL.US) foldable could trigger a decade-long upgrade cycle
Renowned financial journalist Mark Gurman stated that Apple’s first foldable iPhone has the potential to elevate the still-experimental foldable phone category to an industry standard. He noted that this device, called the iPhone Duo, is one of Apple’s most influential products, ranking just behind the iMac, iPod, iPad, and Apple Watch.
Element Fleet drops bid for FleetPartners, exits sale process
Anchoring to Nasdaq! Anthropic races toward a record-breaking IPO with fundraising scale targeting SpaceX
Sources indicate that Anthropic PBC has chosen Nasdaq as its listing venue, and the potential IPO is expected to set a historic record.
Crypto prices
More
